Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Share-based Compensation (2021 - 2025)

ARS Pharmaceuticals' Share-based Compensation history spans 5 years, with the latest figure at $5.7 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 34.58% year-over-year to $5.7 million; the TTM value through Dec 2025 reached $22.1 million, up 52.02%, while the annual FY2025 figure was $22.1 million, 52.02% up from the prior year.
  • Share-based Compensation for Q4 2025 was $5.7 million at ARS Pharmaceuticals, up from $5.7 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $5.7 million in Q4 2025 and bottomed at -$11.2 million in Q4 2021.
  • The 5-year median for Share-based Compensation is $3.9 million (2024), against an average of $3.0 million.
  • The largest annual shift saw Share-based Compensation crashed 93.84% in 2022 before it skyrocketed 752.27% in 2023.
  • A 5-year view of Share-based Compensation shows it stood at -$11.2 million in 2021, then soared by 142.51% to $4.8 million in 2022, then tumbled by 52.17% to $2.3 million in 2023, then skyrocketed by 87.14% to $4.3 million in 2024, then soared by 34.58% to $5.7 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Share-based Compensation are $5.7 million (Q4 2025), $5.7 million (Q3 2025), and $5.4 million (Q2 2025).